Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CNS

This article was originally published in The Tan Sheet

Executive Summary

Breathe Right line extension expected to debut in March 2002, and CNS will enter a new product category later next year, company says during July 19 analysts call on Q2 results. Overall first-half sales reached $42.6 mil. compared to $27.9 mil. a year ago, while Q2 sales grew 16.5% to $15.5 mil., slightly outpacing earlier projections (1"The Tan Sheet" July 2, p. 8). "Disappointing" Fiberchoice sales of $5 mil. in first half causing CNS to reduce second-half marketing expenditures by about $7 mil. compared to first six months, company says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel